 |
Journal articles
A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.
Maria-João Ribeiro
1, *
Stéphane Thobois
2
Ebba Lohmann
3, 4
Sophie Tezenas Du Montcel
5, 6
Suzanne Lesage
7
Antoine Pelissolo
8
Bruno Dubois
3, 4, 9
Luc Mallet
7, 10
Pierre Pollak
11
Yves Agid
3, 12
Emmanuel Broussolle
2
Alexis Brice
3, 13
Philippe Remy
14, 15
*
Corresponding author
Maria-João Ribeiro 1
Correspondent author
Stéphane Thobois 2
Author
Ebba Lohmann 3, 4
Author
Sophie Tezenas Du Montcel 5, 6
Author
Suzanne Lesage 7
Author
Antoine Pelissolo 8
Author
Bruno Dubois 3, 4, 9
Author
Luc Mallet 7, 10
Author
Pierre Pollak 11
Author
Yves Agid 3, 12
Author
Emmanuel Broussolle 2
Author
Alexis Brice 3, 13
Author
Philippe Remy 14, 15
Author
1
SHFJ - Service Hospitalier Frédéric Joliot (France)
- DRF (CEA) - Direction de Recherche Fondamentale (CEA) : DRF/JOLIOT (Direction de Recherche Fondamentale
Fundamental Research Division
CEA Saclay
91191 Gif-sur-Yvette
- France)
- CEA - Commissariat à l'énergie atomique et aux énergies alternatives (Centre de Saclay Centre de Grenoble Centre de Cadarache etc - France)
- Université Paris-Saclay (Espace Technologique, Bat. Discovery - RD 128 - 2e ét., 91190 Saint-Aubin - France)
2
Hôpital Neurologique (Bron - France)
- HCL - Hospices Civils de Lyon (3 Quai des Célestins 69002 Lyon - France)
- Université de Lyon (92 rue Pasteur - CS 30122, 69361 Lyon Cedex 07 - France)
3
CRICM - Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (GH Pitié-Salpêtrière 47, boulevard de l'Hôpital 75651 Paris cedex 13 - France)
- UPMC - Université Pierre et Marie Curie - Paris 6 (4 place Jussieu - 75005 Paris - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U975 (101, rue de Tolbiac, 75013 Paris - France)
- CNRS - Centre National de la Recherche Scientifique : UMR7225 (France)
4
CHU Pitié-Salpêtrière [AP-HP] (47-83 Boulevard de l'Hôpital, 75013 Paris - France)
5
Service de biostatistiques et information médicale [CHU Pitié-Salpêtrière] (47-83, boulevard de l'Hôpital 75651 PARIS Cedex 13 - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- CHU Pitié-Salpêtrière [AP-HP] (47-83 Boulevard de l'Hôpital, 75013 Paris - France)
6
Modelisation in Clinical Research (Paris - France)
- UPMC - Université Pierre et Marie Curie - Paris 6 (4 place Jussieu - 75005 Paris - France)
7
Neurologie et thérapeutique expérimentale (GH Pitié-Salpetrière 47, Boulevard de L'Hopital 75651 PARIS CEDEX 13 - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : U679 (101, rue de Tolbiac, 75013 Paris - France)
- IFR70 (France)
- UPMC - Université Pierre et Marie Curie - Paris 6 (4 place Jussieu - 75005 Paris - France)
8
Service de psychiatrie adulte [CHU Pitié-Salpêtière] (47-83, boulevard de l'Hôpital 75651 PARIS Cedex 13 - France)
- UPMC - Université Pierre et Marie Curie - Paris 6 (4 place Jussieu - 75005 Paris - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- CHU Pitié-Salpêtrière [AP-HP] (47-83 Boulevard de l'Hôpital, 75013 Paris - France)
9
Centre de référence sur les démences rares et maladie de Pick (Paris - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- CHU Pitié-Salpêtrière [AP-HP] (47-83 Boulevard de l'Hôpital, 75013 Paris - France)
10
Behavior, Emotion and Basal Ganglia (Paris - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : - AVENIR GROUP (101, rue de Tolbiac, 75013 Paris - France)
- Center of Clinical Investigation (France)
11
Département de neurologie (Grenoble - France)
- UJF - Université Joseph Fourier - Grenoble 1 (BP 53 - 38041 Grenoble Cedex 9 - France)
- CHU Grenoble (France)
12
CIC AP-HP (pitie-Salpetriere)/inserm (Gh Pitie-Salpetriere PARIS VI 47, Boulevard de L'Hopital 75651 PARIS CEDEX 13 - France)
- UPMC - Université Pierre et Marie Curie - Paris 6 (4 place Jussieu - 75005 Paris - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : CIC9503 (101, rue de Tolbiac, 75013 Paris - France)
13
Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière] (47-83, boulevard de l'Hôpital 75651 PARIS Cedex 13 - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- CHU Pitié-Salpêtrière [AP-HP] (47-83 Boulevard de l'Hôpital, 75013 Paris - France)
14
Service de néphrologie et transplantation (51, av du Maréchal de Tassigny, 94010 Créteil - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- Hôpital Henri Mondor (France)
- UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12 (61 avenue du Général de Gaulle - 94010 Créteil cedex - France)
15
Hôpital Henri Mondor (Créteil - France)
- AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) (France)
- Hôpital Henri Mondor (France)
- UPEC UP12 - Université Paris-Est Créteil Val-de-Marne - Paris 12 (61 avenue du Général de Gaulle - 94010 Créteil cedex - France)
Abstract : The impact of parkin gene mutations on nigrostriatal dopaminergic degeneration is not well established. The purpose of this study was to characterize by PET using (18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-fluoro-l-DOPA), (11)C-PE2I, and (11)C-raclopride the pattern of dopaminergic lesions in young-onset Parkinson disease (YOPD) patients with or without mutations of the parkin gene and to correlate the clinical and neuropsychologic characteristics of these patients with PET results. METHODS: A total of 35 YOPD patients were enrolled (16 with parkin mutation, 19 without). The uptake constant (K(i)) of (18)F-fluoro-l-DOPA and the binding potential (BP) of (11)C-PE2I (BP(DAT)) and of (11)C-raclopride (BP(D2)) were calculated in the striatum. Comparisons were made between the 2 groups of YOPD and between controls and patients. For each radiotracer, parametric images were obtained, and statistical parametric mapping (SPM) analysis using a voxel-by-voxel statistical t test was performed. Correlations between the cognitive and motor status and PET results were analyzed. RESULTS: In YOPD patients, (18)F-fluoro-l-DOPA K(i) values were reduced to 68% (caudate) and 40% (putamen) of normal values (P < 0.0001). This decrease was symmetric and comparable for nonparkin and parkin patients. No correlation was found between the K(i) values and cognitive or motor status. (11)C-PE2I BP(DAT) values in YOPD patients were decreased to 56% (caudate) and 41% (putamen) of normal values (P < 0.0001) and did not differ between the 2 YOPD populations. The mean (11)C-raclopride BP(D2) values were reduced to 72% (caudate) and 84% (putamen) of the normal values (P < 0.02) and did not differ between nonparkin and parkin patients. SPM analyses showed in patients an additional decrease of (11)C-raclopride in the frontal cortex and a decrease of (18)F-fluoro-l-DOPA and (11)C-PE2I uptake in the substantia nigra bilaterally (P < 0.05, false-discovery rate-corrected). CONCLUSION: Carriers of parkin mutations are indistinguishable on PET markers of dopaminergic dysfunction from other YOPD patients with long disease duration.
Document type :
Journal articles
Complete list of metadatas
https://www.hal.inserm.fr/inserm-00529647
Contributor : Marc Savasta <>
Submitted on : Tuesday, October 26, 2010 - 11:16:47 AM
Last modification on : Friday, November 6, 2020 - 4:09:40 AM
Contributor : Marc Savasta <>
Submitted on : Tuesday, October 26, 2010 - 11:16:47 AM
Last modification on : Friday, November 6, 2020 - 4:09:40 AM
Links full text
Identifiers
- HAL Id : inserm-00529647, version 1
- DOI : 10.2967/jnumed.109.063529
- PUBMED : 19617340
Collections
Citation
Maria-João Ribeiro, Stéphane Thobois, Ebba Lohmann, Sophie Tezenas Du Montcel, Suzanne Lesage, et al.. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.. Journal of Nuclear Medicine, Society of Nuclear Medicine, 2009, 50 (8), pp.1244-50. ⟨10.2967/jnumed.109.063529⟩. ⟨inserm-00529647⟩
Metrics
Record views